Hyloris Lines Up Hectic Year Of Clinical Trials And Major US Launch
Value-Added Medicines Developer Quietly Reframes 30-Asset Goal
Hyloris has an eventful year ahead as it plans to conduct numerous trials for products in its ever-expanding pipeline and launch Maxigesic IV in the US.
You may also be interested in...
Hyloris Submits Additional Data For Maxigesic IV Filing To US FDA
Hyloris has submitted additional data to the US Food and Drug Administration about its value-added analgesic Maxigesic IV, following enquiries about potential extractable and leachable compounds expected to be present in the product due to the packaging.
Hyloris Ramps Up Product Expansion With New Idiopathic Rhinitis Spray
Hyloris Pharmaceuticals’ new idiopathic rhinitis treatment sets it on track to achieve its target of around 30 portfolio assets by the end of 2024.
FDA Asks Hyloris For More Data On Maxigesic IV
Hyloris has received a complete response letter from the US FDA asking for more information on its 505(b)(2) hybrid application for its Maxigesic IV intravenous analgesic for treating post-operative pain.